Novartis has upgraded its mid-term sales guidance to +6% CAGR for 2023-2028 and +5% for 2024-2029, driven by strong momentum in its business. The company boasts 8 in-market brands with $3bn+ to $8bn+ peak sales potential and over 15 near-term submission-enabling readouts. Novartis remains on track to achieve a core operating income margin of 40%+ by 2027.The company's pipeline includes 30+ high-value medicines expected to support continued mid-single digit sales growth beyond 2029. Novartis has executed more than 30 strategic deals in the last two years, primarily in early-stage research. Recent acquisitions include Kate Therapeutics and a licensing agreement with Ratio Therapeutics, enhancing its gene therapy and radioligand therapy capabilities.Novartis has completed its transformation into a pure-play innovative medicines company, focusing on core therapeutic areas and technology platforms. The company's capital allocation policy includes value-creating bolt-on acquisitions to complement its internal innovation engine. Novartis remains confident in its focused strategy and ability to deliver sustainable value creation for shareholders.

Novartis has upgraded its mid-term sales guidance to +6% CAGR for 2023-2028 and +5% for 2024-2029, driven by strong momentum in its business. The company boasts 8 in-market brands with $3bn+ to $8bn+ peak sales potential and over 15 near-term submission-enabling readouts. Novartis remains on track to achieve a core operating income margin of 40%+ by 2027.The company's pipeline includes 30+ high-value medicines expected to support continued mid-single digit sales growth beyond 2029. Novartis has executed more than 30 strategic deals in the last two years, primarily in early-stage research. Recent acquisitions include Kate Therapeutics and a licensing agreement with Ratio Therapeutics, enhancing its gene therapy and radioligand therapy capabilities.Novartis has completed its transformation into a pure-play innovative medicines company, focusing on core therapeutic areas and technology platforms. The company's capital allocation policy includes value-creating bolt-on acquisitions to complement its internal innovation engine. Novartis remains confident in its focused strategy and ability to deliver sustainable value creation for shareholders.